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Key Points
• The vascular S1P
gradient is dispensable
for platelet formation
in mice.
• Instead, local S1P
production restrains
megakaryopoiesis via
S1P1 and can further
suppress platelet
production via S1P2
when deregulated.
The bioactive lipid mediator sphingosine 1-phosphate (S1P) was recently assigned critical
roles in platelet biology: whereas S1P1 receptor-mediated S1P gradient sensing was
reported to be essential for directing proplatelet extensions from megakaryocytes (MKs)
toward bonemarrow sinusoids, MK sphingosine kinase 2 (Sphk2)–derived S1P was reported
to further promote platelet shedding through receptor-independent intracellular actions,
and platelet aggregation through S1P1. Yet clinical use of S1P pathway modulators
including fingolimod has not been associated with risk of bleeding or thrombosis. We
therefore revisited the role of S1P in platelet biology in mice. Surprisingly, no reduction
in platelet counts was observed when the vascular S1P gradient was ablated by impairing
S1P provision to plasma or S1P degradation in interstitial fluids, nor when gradient sensing
was impaired by S1pr1 deletion selectively in MKs. Moreover, S1P1 expression and
signaling were both undetectable in mature MKs in situ, and MK S1pr1 deletion did not
affect platelet aggregation or spreading. When S1pr1 deletion was induced in hematopoietic
progenitor cells, platelet counts were instead significantly elevated. Isolated global Sphk2
deficiency was associated with thrombocytopenia, but this was not replicated by
MK-restricted Sphk2 deletion and was reversed by compound deletion of either Sphk1 or
S1pr2, suggesting that this phenotype arises from increased S1P export and S1P2 activation
secondary to redistribution of sphingosine to Sphk1. Consistent with clinical observations,
we thus observe no essential role for S1P1 in facilitating platelet production or activation.
Instead, S1P restricts megakaryopoiesis through S1P1, and can further suppress thrombo-
poiesis through S1P2 when aberrantly secreted in the hematopoietic niche.
Introduction
Sphingosine-1-phosphate (S1P) is a lipid mediator that plays critical roles in the homeostasis of vascular
and immune systems.1 Although most of its functions are mediated by 5 cognate G protein-coupled
receptors (S1P1-5; encoded by S1pr1-5), S1P also plays intracellular receptor-independent roles.
1
Submitted 21 January 2019; accepted 17 April 2019. DOI 10.1182/
bloodadvances.2019031948.
*H.N. and N.Z. contributed equally to this study.
For original data, please contact eric.camerer@inserm.fr.
The full-text version of this article contains a data supplement.
1702 11 JUNE 2019 x VOLUME 3, NUMBER 11
Sphingosine is phosphorylated to S1P by sphingosine kinases
(Sphk) 1&2.2,3 Compound deletion of Sphk1&2 results in a tissue-
wide loss of S1P, isolated Sphk1 deletion in a ;50% reduction in
plasma S1P and complete loss of red blood cell (RBC) S1P, and
Sphk2 deletion in a paradoxical doubling of plasma S1P and near-
complete loss of megakaryocyte (MK)/platelet S1P.4-9 While
RBCs and endothelial cells continuously export S1P to plasma
and lymph through transporters Mfsd2b and spinster 2, respec-
tively, S1P is actively broken down and removed from interstitial
fluids by S1P lyase (encoded by Sgpl1) and lipid phosphatases.10-15
Platelets store abundant S1P, roughly equivalent to the plasma pool,
that can be exported by Mfsd2b on activation.6,11,14
Combined with a short half-life, tight control of export and
degradation thus allows the maintenance of a steep gradient
of S1P between blood and interstitial fluids that is used by
hematopoietic cells to gauge their proximity to blood and
lymph.10,16 When sensed by S1P1, S1P drives lymphocytes
into circulation by activation of Gai and Rac; when sensed by
S1P2, it confines lymphocytes within germinal centers through
Ga12/13 and RhoA.
17-19 Plasma membrane receptor expres-
sion thereby dictates how a cell responds to S1P. S1P1 is internalized
once cells reach the circulation and are exposed to receptor-
saturating S1P levels, and reexpressed after cells are attracted back
to S1P-poor environments by other chemokines.10 The clinically
approved multiple sclerosis drug fingolimod (AKA FTY720,
Gilenya) induces immunosuppression by disruption of S1P1-
mediated gradient sensing. Once phosphorylated by Sphk2,
fingolimod acts as a functional antagonist of S1P1, first
activating and then rapidly desensitizing the receptor.10,16
Fingolimod also targets S1P3-5.
1
MKs were recently proposed to use S1P1 to direct proplatelet
(PP) extensions along the S1P gradient toward bone marrow
sinusoids, and for subsequent platelet shedding, as schemati-
cally presented in Figure 1A.20,21 A parallel, MK-intrinsic receptor-
independent role for S1P was proposed in platelet shedding
(Figure 1A),22 and platelet-derived S1P and S1P1 have been
further implicated in the amplification of platelet aggregation
during arterial thrombosis.7 S1P4 is also involved in terminal dif-
ferentiation of MKs, although S1P4-deficient animals have normal
platelet counts.23 Together, these studies position S1P as a
key player in platelet production and function. Fingolimod and
S1P1-selective modulators are being explored for the treat-
ment of a range of disease conditions, some of which are as-
sociated with risk of hemorrhage and thrombosis.1,24 Sphks
and S1P lyase are also emerging as potential drug targets for
treatment of cancer, pulmonary hypertension, bone loss, and
sickle cell disease.24-26 Should it be a concern that these drugs
also target S1P production and signaling in MKs and platelets?
In this regard, it is reassuring that case reports of thrombocy-
topenia and bleeding in patients with MS receiving fingolimod
are rare, and that pilot trials with fingolimod for ischemic and
hemorrhagic stroke have not revealed an increase in bleeding
propensity.27,28 Whether this reflects on the complex mecha-
nisms of action of fingolimod or if experimental studies have
overestimated the role of S1P1 in platelet production and
function is unclear.
The role for S1P gradient sensing in lymphocyte trafficking was
demonstrated by rendering either interstitial fluids S1P-rich by
inhibiting S1P lyase, or blood and lymph S1P-poor by tissue-
specific Sphk1&2 deletion.10 A key role for S1P1 was suggested
using S1P1-modulating drugs and established by hematopoietic
or lymphocyte selective deletion of S1pr1.10,29,30 Using similar tools
to interrogate the role of S1P in platelet biology, we fail to confirm a
critical role for the S1P gradient and S1P1 in platelet production or
function, consistent with clinical observations. We instead reveal
that S1P1 signaling in the hematopoietic compartment restrains
megakaryopoiesis, and that aberrant S1P2 activation can further
suppress platelet production when S1P is released in the hema-
topoietic niche.
Materials and methods
Generation and validation of conditional (f) and global (2) knock-
outs of Sphk1, Sphk2, S1pr1, and Sgpl1 (encoding Sphk1,
Sphk2, S1P1, and S1P lyase, respectively), plasma S1Pless mice
(Sphk1f/2:2f/2:Mx1Cre1), platelet S1Pless mice (Sphk1f/2:2f/2:Pf4Cre),
S1P1 ECKO mice (S1pr1
f/f:PdgfbCre1), and S1P1 signaling reporter
mice (S1pr1GFP) has been described.6,11,31-34 Mice deficient in S1pr1
or Sphk2 in MKs and platelets (S1pr1f/f:Pf4Cre1; Sphk2f/f:Pf4Cre1)
were generated with Cre recombinase driven by the platelet factor 4
promoter.35 Experiments were littermate controlled. Complete blood
cell counts were obtained with a HemaVet (Drew Scientific). Scanning
and transmission electron microscopy was performed as previously
described.6,36 S1P and sphingosine concentrations in plasma and cell
lysates were quantified by liquid chromatography/tandem mass spec-
trometry and high-performance liquid chromatography, as described.6
Bone marrow (BM) hematopoietic stem cells (Lin2:Sca-11:c-Kit1),
commonMK/erythrocyte progenitor cells (Lin2:Sca-12:c-Kit1:CD342:
CD16/322), and MK progenitor cells (MKPs; lineage2:Sca-12:c-Kit1:
CD342:CD16/322:CD411) were quantified by flow cytometry.
Reagents and methods for platelet isolation and functional analyses,
platelet half-life, microcomputed tomography imaging and analy-
ses, further immunohistochemical analyses, quantitative polymer-
ase chain reaction, MK culture, and platelet formation are
detailed in supplemental Information. Experimental procedures
involving animals were approved by the Paris Descartes Ethical
Committee and the French Ministry of Education. Statisti-
cal significance was assessed using GraphPad Prism soft-
ware; details of tests used are provided in the figure legends.
*P , .05, **P , .01, ***P , .001, and ***P , .0001.
Results
The S1P gradient is dispensable for
platelet production
We and others have reported that compound deletion of Sphk1&2
in hematopoietic and other Mx1Cre-sensitive cells greatly re-
duces RBC, platelet, and plasma S1P levels, and that S1P lyase
deficiency increases serum S1P levels more than threefold and
tissue S1P greatly, both resulting in profound lymphopenia
resulting from ablation of the S1P gradient.6,11,32,33,37 Current
literature predicts that combined loss of the S1P gradient and
MK S1P production should result in equally profound thrombo-
cytopenia from additive effects of defective PP formation and
fragmentation (Figure 1A).1,20-22 We were therefore surprised to
observe that peripheral blood platelet counts in mice lacking S1P
in both plasma and MKs (Sphk1f/2:2f/2:Mx1Cre1) were instead
higher than in littermate controls, whereas alternative S1P
gradient disruption with S1P lyase deficiency (Sgpl12/2) had no
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effect on platelet counts, despite expected lymphopenia in both
models (Figure 1B). Murine thrombopoiesis is therefore criti-
cally dependent neither on the S1P gradient20 nor on MK S1P
production.22
S1P1 suppresses platelet production by a
non-cell-autonomous mechanism
We next asked if S1P1 promotes platelet production indepen-
dent of gradient sensing. Fingolimod both activates and desen-
sitizes S1P1, thus disrupting S1P1-mediated S1P sensing.
Administration of fingolimod (2 mg/L) to the drinking water of wild-
type mice for 1 week impaired lymphocyte trafficking, but had no
effect on platelet counts (Figure 1C). Postnatal deletion of S1pr1
in hematopoietic and other Mx1Cre-sensitive cells also yielded
profound lymphopenia, but unexpectedly, a significant increase
rather than a decrease in platelet counts (Figure 1D). This was
replicated by constitutive pan-hematopoietic deletion of S1pr1 with
Vav1Cre, whereas restricted deletion in MKs with Pf4Cre35 or
endothelial cells and a subset of MKs with PdgfbCre38 had no
effect on platelet or lymphocyte counts (Figure 1D). When Mx1Cre-
mediated S1pr1 excision was induced in adulthood or when
S1pr1f/fMx1Cre1 BM cells were transplanted into lethally irradiated
wild-type recipients, we observed lymphopenia but not thrombocy-
tosis (Figure 1E-F). This argued that hematopoietic S1P1 signaling
has an indirect and delayed negative effect on platelet production.
Concordantly, 24-hour platelet counts were not altered by selective
S1P1 agonism (SEW2871; 1 or 10 mg/kg) or antagonism (W146;
10 mg/kg39 or 4 3 3 mg/kg at 6-hour intervals20; Figure 1G),
although SEW2871 did induce transient lymphopenia and W146
vascular leak, as has been reported (supplemental Figure 1A-C).40,41
Mx1Cre-mediated S1pr1 deletion did not affect platelet half-
life or size, nor plasma S1P levels, consistent with a role in
megakaryopoiesis (Figure 1H). Neonatal and constitutive hema-
topoietic S1pr1 deletion also yielded a significant reduction in
RBC counts that was neither conferred by BM transplantation nor
induced with Mx1Cre-mediated S1pr1 deletion in adulthood, but
was also observed with neonatal Sphk1&2 deletion (Figure 1I).
This may suggest that S1P1 signaling influences fate decisions of
a common progenitor, although delayed effects could also reflect
indirect roles of hematopoietic S1P1 signaling in bone develop-
ment or tissue distribution of progenitors.42-45 As Mx1Cre is active
in osteoclasts and deletion of S1pr1 in osteoclasts has been
demonstrated to increase their attachment to the bone surface,
triggering osteoporosis,46 we evaluated bone density in neonatally
induced S1pr1f/f-Mx1Cre1 mice. If anything, microcomputed tomog-
raphy analysis suggested a modest increase in bone density in young
adults (Figure 1J; supplemental Figure 2), unlikely to directly affect
megakaryopoiesis.47 Although we did not observe a significant effect
of S1P1 deficiency on the number of hematopoietic stem cells,
MK-erythroid progenitors, or MKPs in BM, a modest increase in the
abundance of MKs in BM and spleen was nevertheless suggestive
of an increase in megakaryopoiesis sufficient to explain the increase
in platelet counts (Figure 1K; supplemental Figure 3). Collectively,
these observations argue that not only is S1P1 dispensable for
thrombopoiesis, but also that it is a net negative regulator of
platelet production.
S1P1 is not expressed in murine MKs
As our findings directly contradict the critical role reported for S1P1
in MKs,20 we next addressed the efficiency of our genetic approaches.
S1P1 was undetectable on S1pr1
f/f:Pf4Cre1 and S1pr1f/f:Mx1Cre1
splenic and BM MKs (Figure 2A). Surprisingly, we also did not
observe MK S1P1 in controls, despite readily detectable S1pr1-
dependent endothelial immunostaining (Figure 2A; supplemental
Figure 4). To address if S1P1 was functionally expressed be-
low the detection limit of our immunostaining, we visualized S1P1
signaling in BM, spleen, and liver of naive and S1P1 agonist-treated
S1P1 signaling reporter mice.
34 Nuclear GFP accumulation reflected
S1P1 signaling in a subset of endothelial cells and hematopoi-
etic cells in BM and spleen that appeared more abundant after
treatment with fingolimod and the S1P1 selective agonists RP001,
both of which also induced marked GFP accumulation in hepato-
cytes (Figure 2B; supplemental Figure 5). In contrast, MKs were
consistently GFP negative, independent of treatment. Moreover,
consistent with reported downregulation of S1P1 transcription with
progenitor cell commitment to the MK lineage,23 BM-derived MKs
expressed S1P2 and S1P4, but no detectable S1P1 (Figure 2C). The
same primers readily amplified S1P1 from total lung cDNA (not
Figure 1. MK S1P, S1P1S1P, and the S1P gradient are dispensable for platelet production in mice. (A) Current literature suggests that S1P supports platelet
production by 2 independent mechanisms: S1P1 senses the S1P gradient to promote PP extensions toward blood sinusoids (purple) and further supports fragmentation,
and S1P supports platelet fragmentation by receptor-independent promotion of Src family kinase (SFK) expression and activation in MKs (orange). Removal of the S1P
gradient and MK S1P production would thus be predicted to have cumulative effects on platelet production. Target cells of Cre alleles used in this study are indicated.
(B) Peripheral blood platelet and lymphocyte counts in mice with combined loss of lymphatic endothelium and hematopoietic S1P production (Sphk1f/2:2f/2:Mx1Cre1)
and with alternative gradient ablation by impaired S1P breakdown (Sgpl12/). (C) Relative changes in the same cell populations after supplying the functional S1P1
antagonist fingolimod (2 mg/L) in the drinking water of wild-type mice for 1 week. (D) Platelet and lymphocyte counts in mice after deletion of S1pr1 in hematopoietic
and other cells (postnatal induction, Mx1Cre1), in all hematopoietic cells (constitutive deletion, Vav1 Cre1), in MKs (constitutive deletion; Pf4Cre1), or endothelial cells
and MKs (postnatal induction, PdgfbiCreERT21). (E-F) Platelet and lymphocyte counts in adult S1pr1f/f:Mx1Cre1/2 mice 1 month after 3 consecutive injections of
Poly IC (E) or in lethally irradiated wild-type mice 1 month after transfusion of S1pr1f/f:Mx1Cre1/2 BM cells (F). (G) Relative change in platelet counts 24 hours after
injections of the S1P1 agonist SEW2871 or antagonist W146 or respective vehicle controls, as indicated (W146 was injected either as a single bolus [middle] or at 0, 6,
12, and 18 hours [right]). Lymphocyte counts and acute effects of drug treatment in supplemental Figure 1. (H) Platelet half-life, mean platelet volume (MPV), and plasma
S1P levels in S1pr1f/f:Mx1Cre1 mice. (I) RBC counts in mice with hematopoietic deletion of S1pr1 or Sphk1&2 (the same mice as in Figure 1D, 1F, 1E, and 1B,
respectively). (J) Representative microcomputed tomography images of femurs from S1pr1f/f:Mx1Cre1 mice and littermate controls. Representative coronal and
transverse sections (approximate area indicated) are shown, quantification in supplemental Figure 2. (K) BM progenitors as percentage of total bone marrow cells and MK
density in BM and spleen of S1pr1f/f:Mx1Cre1 mice. Representative images in supplemental Figure 3. All animals are compared with their respective littermate controls,
n indicates the number of animals from which samples were obtained, mean 1 standard error of the mean shown. Statistical analyses by Mann-Whitney U test. ns, not
significant.
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shown). Transcriptional analysis also did not reveal compensa-
tory upregulation of other S1P receptors in the absence of S1P1
(Figure 2C). Analysis of genomic DNA from BM-derived MKs from
the same lines showed more than 98%, more than 90%, and
more than 50% excision of S1pr1 with Mx1Cre, Pf4Cre, and
PdgfbCre, respectively (Figure 2D). As ;70% of fluorescence-
activated cell sorter sortable cells (including progenitors and
excluding very mature MKs) from these cultures expressed CD41,
we conclude that Mx1Cre and Pf4Cre both yielded near complete
genomic excision in MKs, whereas excision with PdgfbCre was either
partial or more restricted to mature MKs. Accordingly, PdgfbCre showed
partial activation of an eYFP reporter in splenic MKs (supplemental
Figure 6). This argues that S1P1 is not expressed on murine MKs,
militating against even a nonessential role for MK S1P1 in thrombopoi-
esis, and further arguing that increased platelet counts observed with
pan-hematopoietic S1P1 deficiency reflect actions in MK progenitors.
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Figure 2. S1P1 is not expressed in murine MKs. (A) Expression of S1P1 (red) and the MK marker CD41 (green) in spleen of mice with or without MK-selective
(S1pr1f/f:Pf4Cre1) or pan-hematopoietic (S1pr1f/f:Mx1Cre1) S1P1 deletion. Note S1P1 expression in blood vessels and white pulp, but not in MKs, irrespective of
gene deletion. Scale bars represent 50 mm. (B) Constitutive (left) and fingolimod-induced (1 mg/kg, 24 hours; right) S1P1 signaling in spleens of S1P1 signaling reporter
mice.34 Note constitutive and fingolimod-enhanced S1P1 signaling (reflected by nuclear GFP accumulation in green) in blood vessels (in red) and cells within the white
pulp, but not MKs (in blue). Scale bars represent 50 mm. (C) Abundance of S1PR transcripts in BM-derived MKs from S1pr1-deficient mouse lines relative to
Gapdh. Note lack of S1pr1 expression (mRNA) or compensatory upregulation of other receptors after 3 days of culture. (D) Abundance of nonexcised S1pr1 in
genomic DNA (gDNA) from BM-derived MKs from S1pr1-deficient mouse lines after 5 days of culture relative to pooled S1pr1f/f littermate controls. (E) Relative
abundance of nonexcised S1pr1 in genomic DNA from freshly isolated BM cells from S1pr1-deficient mice passed through 70-mm filters. Statistical analysis by
Mann-Whitney U test. n.d., not detectable.
1706 NIAZI et al 11 JUNE 2019 x VOLUME 3, NUMBER 11
S1P1 is dispensable for activation and spreading of
mouse platelets
These results also question a reported role for S1P1 in platelet
aggregation and thrombosis in mice.7 S1P alone did not trigger
aggregation of washed murine platelets (not shown), although it
slightly enhanced PAR4 activating peptide (PAR4-AP)-induced
aggregation (Figure 3A). This effect of S1P persisted in the
absence of S1pr1, and pharmacologic S1P1 modulators did not
affect PAR4-AP-induced platelet aggregation (Figure 3A). S1P1
deficiency also did not affect ADP-induced platelet aggregation
in the presence or absence of exogenous S1P at a concentration
suggested to modulate platelet activation,7 even when sensitizing
the system by inhibiting P2Y12-mediated Gai activation with
2MeSAMP. Platelet adhesion and spreading on fibrinogen were also
unaffected by S1pr1 deletion, S1P addition, or S1P1 antagonism
(Figure 3B; supplemental Figure 7). Thus, aggregation, spreading,
and thrombosis phenotypes reported in Sphk-deficient platelets6,7
and mice7 likely reflect on activation of a different receptor, receptor-
independent effects, or thrombocytopenia,22 rather than on a role for
S1P1 in platelet activation.
7
Deregulated S1P production by Mx1Cre-sensitive
hematopoietic cells suppresses thrombopoiesis in
Sphk22/2 mice
Increased platelet counts in Sphk1f/2:2f/2:Mx1Cre1 mice (Figure 1B)
not only argue against a necessary role for the S1P gradient20 but also
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Figure 3. Platelet S1P1 is dispensable for platelet aggrega-
tion and spreading in mice. Platelets from mice in which S1pr1
was deleted in MKs (S1pr1f/f:Pf4Cre1; green), littermate controls
(orange), or wild-type mice (gray) were isolated, washed, and
tested for their capacity to aggregate (A) and spread (B).
(A, upper) Platelet aggregation in response to submaximal concen-
trations (25 mM) of PAR4-AP (thrombin receptor agonist) in the
absence (left) or presence of exogenous S1P (0.1-10 mM; middle)
or of S1P1 agonist SEW-2871 (0.5 mM; right). (A, lower) Platelet
aggregation in response to submaximal PAR4-AP in the presence
of S1P (0.1 mM) in the presence or absence of S1P1 antagonist
W146 (10 mM; left) or in response to the weak platelet agonist
ADP (2 mM; right), with and without exogenous S1P (10 mM) or
P2Y12 antagonism (2MeSAMP, 40 mM) to address potential
redundancy with P2Y12, which, similar to S1P1, is Gai coupled.
(B) Representative scanning electron microscopy images (upper)
showing the extent of platelet spreading 15 and 30 minutes after
plating on fibrinogen in the presence of S1P (0.5 mM; quantifica-
tion in supplemental Figure 7). Note that although S1P did not
trigger aggregation (not shown), it slightly increased PAR4-AP
induced aggregation. However, neither aggregation nor spreading
was influenced by selective S1P1 modulation or S1pr1 deficiency.
S1P also could not compensate for the absence of functional
P2Y12 by alternative engagement of Gai. Statistical analyses
by 2-way analysis of variance or the Mann-Whitney U test, as
appropriate. Mean 6 standard deviation is shown, symbols
represent the number of mice.
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against a necessary intracellular, receptor-independent role for S1P
in platelet production.22 The latter was deduced from the observation
that mice globally deficient in Sphk2 display relative thrombocyto-
penia and defective PP fragmentation.22 We confirmed a 25%
reduction in circulating platelets and a slight increase in mean platelet
volume (MPV) in Sphk22/2 mice; an intermediate phenotype in
Sphk21/2 littermates suggested a dose-dependent effect of Sphk2
deficiency (Figure 4A). As reported, the phenotype was present,
although less profound, when the line was inbred to C57BL/6J
background, and Sphk1 deficiency did not influence platelet counts
despite being associated with a ;50% reduction in plasma S1P
levels (supplemental Figure 8A).22 Bone density, BM progenitors,
platelet life span, and spleen size were unaltered, and genotype-
dependent differences in platelet counts persisted after splenec-
tomy (supplemental Figure 8B-F). Despite thrombocytopenia, MK
numbers were higher in spleen and BM, consistent with a defect
in thrombopoiesis (supplemental Figure 8G-H).22 Although PPs
appeared larger, as reported by Zhang et al,22 we did not observe a
decrease in the capacity of fetal liver-derived MKs to produce PPs
and shed platelets (supplemental Figure 8I). Concordantly, isolat-
ed deletion of Sphk2 in MKs had no effect on platelet counts
(Figure 4B). Consistent with a paracrine effect of Sphk2 deficiency
on MK function, Sphk2 deletion with Lyve1Cre, active in lymphatic
endothelial cells, some blood endothelial cells, macrophages, and
other CD451 cells,48 did reduce platelet counts (Figure 4B). This
presented the possibility that the apparent increase in platelet counts
in plasma S1Pless mice (Sphk1f/2:Sphk2f/2:Mx1Cre1; Figure 1B)
represented a rescue of Sphk21/2-induced thrombocytopenia
(Figure 4A) with pan-hematopoietic Sphk1 deficiency. This would
imply that the Sphk22/2 phenotype results from a redistribution of
sphingosine toward Sphk1 rather than from loss of Sphk2-derived
S1P (Figure 4C).16 Consistent with this notion, sphingo-
sine did not build up in BM cells, as observed in plasma and
RBCs of Sphk22/2 mice; Sphk1 expression remained unaltered
(Figure 4D).9 To test this possibility more directly, we deleted
Sphk1 in Mx1Cre-sensitive cells in a background globally deficient
in Sphk2 (Sphk1f/f:22/2:Mx1Cre1). Consistent with our hypoth-
esis, this returned platelet counts to wild-type levels (Figure 4E).
The rescue was conferred by bone marrow transplantation
(Figure 4F), but was not reproduced with selective Sphk1 deletion
in MKs in a Sphk22/2 background (Figure 4G). Compound deletion
of the 2 kinases did not significantly affect MKP numbers or
platelet life span, and therefore did not appear to provide rescue
by an independent mechanism (Figure 4H). Thus, instead of
reflecting on a critical intracellular signaling role for Sphk2-derived
S1P in MKs, thrombocytopenia in Sphk2-deficient mice appears
to arise from paracrine effects of S1P generated on redistribution
of hematopoietic cell sphingosine to Sphk1.
Deregulated S1P production suppresses
thrombopoiesis via S1P2
The above results suggest that Sphk2 deficiency induces thrombo-
cytopenia by a receptor-dependent mechanism, and we further
show that S1P1 can suppress megakaryopoiesis. However, S1P1
antagonism did not ameliorate thrombocytopenia in Sphk22/2 mice,
whereas antagonism of S1P2, which is expressed on murine MKs
(Figure 2C),20,23 did (Figure 5A). S1P2 deficiency did not by itself
affect platelet production (Figure 5B), but when S1pr21/2 inter-
crosses were performed in an Sphk22 /2 background, S1P2
deficiency rescued Sphk22/2-induced thrombocytopenia (Figure 5C).
Conversely, when Sphk21 /2 intercrosses were performed in
an S1pr22 /2 background, Sphk2 deficiency no longer induced
thrombocytopenia (Figure 5D vs Figure 4A). MPVs were also
normalized by S1P2 deficiency (Figure 5C-D). Transmission electron
microscopy revealed a high density of MKs in Sphk22/2 BM
(Figure 5E). Among these, we observed peri-sinusoidal MKs with
scarce demarcation membrane systems (DMS), poorly resolved
DMS regions sometimes without granules, and low-contrast MK
“ghosts” that appeared to be undergoing necrosis. This contrasted
with Sphk21/1:S1pr21/1 and Sphk22/2:S1pr22/2 BM, in which
most mature MKs were large with well-defined DMS. This suggests
that aberrant S1P2 activation impairs MK maturation. S1P2 is known
to repel B cells when they encounter high S1P concentrations at the
germinal center perimeter, a process that depends on Rho kinase,
which also negatively regulates platelet formation by suppressing
the actions of Rac1 and Cdc42 on cytoskeletal reorganization and
microtubule assembly.17,49-51 Consistent with a role for the Rho
pathway, the Rho kinase inhibitor Y-27632 significantly increased
platelet counts in Sphk2-deficient mice with no effect on littermate
controls (Figure 5F). Collectively, these observations suggest that
Sphk1-derived S1P suppresses MK maturation in Sphk2-deficient
mice by aberrant activation of S1P2 and Rho kinase downstream.
Although compound deficiencies of Sphk1 and S1P2 reversed
Sphk2 deficiency-induced thrombocytopenia, it is noteworthy
that neither fully normalized the MK phenotype in Sphk22/2 mice.
Neither compound deficiency eliminated the higher density of MKs
in Sphk22/2 spleens (supplemental Figure 9), compound Sphk1
deficiency did not normalize MPV in Sphk22/2 mice (Figure 4E),
Sphk22/2 PP extensions appear thicker also ex vivo (supplemen-
tal Figure 8I22), and Sphk-deficient platelets display defective
activation and spreading ex vivo.6,22 These persistent phenotypes
may reflect on imbalanced membrane lipids within Sphk22/2 MKs
and platelets, although not a simple buildup of upstream metab-
olites, as we observed a paradoxical decrease in sphingosine
levels in Sphk-deficient platelets (Figure 5G).6,22
Discussion
We here address roles for S1P in platelet production and function,
using genetic and pharmacologic approaches in mice. Contrasting
recent literature, our observations support neither a necessary role
for the S1P gradient or MK/platelet S1P1 in platelet production
or aggregation nor a necessary intracellular signaling role for S1P
in platelet production. They instead reveal that S1P1 signaling
continuously restrains megakaryopoiesis and that S1P2 signaling
can further suppress platelet production when sphingosine metab-
olism is disturbed in the hematopoietic niche.
Three recent reports have positioned S1P as a critical facilitator
of platelet biogenesis and signaling by S1P1-dependent attraction
of PPs into BM sinusoids and subsequent shedding during plate-
let budding from MKs,20 receptor-independent regulation of plate-
let shedding by Sphk2-derived S1P,22 and amplification of platelet
aggregation by an autocrine S1P1 activation loop acting downstream
of conventional platelet agonists.7 Our observations do not fully
support either model, and argue that S1P plays a limited role in platelet
biology bar major disturbances in S1P metabolism or signaling.
First, we do not observe a necessary role for S1P1-mediated blood
sensing in platelet formation. Genetic impairment of S1P provision
to plasma or S1P breakdown in tissue, both with profound effects
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mice. Statistical analyses by Mann-Whitney U test or 2-way analysis of variance.
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on lymphocyte trafficking, did not reduce platelet counts, nor did
complete or partial deletion of MK S1pr1 by 4 different transgenic
approaches. Also at variance with Zhang et al,20 we did not
observe effects of S1P1-selective pharmacological modulation on
platelet counts when controlling for effects of vehicle and prior
bleeding, nor did we confirm S1P1 expression on murine MKs ex
vivo or in situ. Our experiments were carried out in different strain
backgrounds, littermate controlled, and sufficiently powered
to reveal an important role for S1P gradient sensing. These
observations are also in line with clinical experience, which has not
revealed thrombocytopenia as an important adverse effect of S1P1-
targeting drugs.52,53
In direct contrast, we observed elevated platelet counts with widespread
neonatal deletion of either Sphk1&2 or S1pr1. Although modest, this
effect was highly significant and replicated with constitutive S1pr1
deletion in hematopoietic cells, but not in MKs. Thrombocytosis was
not conferred by transplantation of S1pr1-deficient bone marrow or
inducedwith adult deletion or acute pharmacological S1P1modulation,
suggesting developmental or delayed effects. A slight increase in
MKs and a concomitant decrease in RBC counts suggested that
S1P1 may drive the differentiation of a common progenitor toward
the erythroid lineage. Whether this reflects a direct role for S1P1
signaling in cell fate decisions or indirect effects on the hematopoietic
niche or stem cell trafficking42,45,46 remains to be determined.
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Figure 5. Sphk2 deficiency induces thrombocytopenia by aberrant S1P2 activation. (A) Effects of S1P1 (W146, 10 mg/kg, left) or S1P2 (JTE-013, 1.2 mg/kg)
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analyses by 2-way analysis of variance (A,F) or the Mann-Whitney U test.
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Second, our results do not support a critical intracellular role for
Sphk2-derived S1P in platelet production. As reported in a
second Zhang et al study,22 we observed mild thrombocytope-
nia in Sphk22/2 mice. Yet whereas Zhang et al deduced an
intracellular role for Sphk2-derived S1P from observations in
mice globally deficient in Sphk2, we did not reproduce throm-
bocytopenia with Pf4Cre-mediated selective deletion in MKs,
even if this results in near complete loss of platelet S1P.6
Reversal of Sphk2 deficiency-induced thrombocytopenia with
Sphk1 deletion in hematopoietic cells further suggested that the
phenotype reflected on an increase rather than a decrease in
S1P production, a hypothesis substantiated by similar reversal
with S1P2 deficiency. Although our interpretation of how Sphk2
deficiency induces thrombocytopenia differs, detailed charac-
terization of the phenotype by Zhang et al remains consistent
with our data. Elegant 2-photon microscopy showed abnormal
extension of proplatelets into BM sinusoids of Sphk22/2 mice,
followed by retraction without efficient platelet shedding.22 Our
results suggest that the activation of S1P2 and Rho kinase
downstream could contribute to impaired platelet shedding, and
that disturbed membrane lipid composition could also contrib-
ute to the gross aspects of the phenotype. S1P2 has been
reported to mediate blood repulsion in osteoclast precursors19
and to confine B cells to germinal centers by preventing their exit
to high S1P environment.17 One could thus imagine high plasma
S1P as observed in Sphk2-deficient animals to constitute a
repulsive cue during platelet formation. Yet transfer of thrombo-
cytopenia,22 but not high S1P levels,9 with transfer of Sphk22/2
bone marrow cells does not support this model, and Sphk22/2
PPs extended far into the bone marrow sinusoids before
retracting.22 Impaired MK maturation was reminiscent of
compound deficiency in Cdc42 and Rac1, and our observations
would be consistent with Ga12/13-coupled S1P2 suppressing
Cdc42 and Rac1 through RhoA, thus inhibiting terminal MK
maturation or platelet shedding.20,49
Third, our results argue against an important role for S1P1 in
amplifying platelet aggregation. Urtz et al reported protection from
arterial thrombosis with global Sphk2 deficiency and reduced platelet
aggregation in response to thrombin and other agonists in platelets
derived from these mice.7 This phenotype was attributed to a lack of
activation of platelet S1P1 by platelet-derived S1P, based mainly on
studies performed in human platelets or whole blood.7 Although we
previously confirmed defective aggregation and spreading in Sphk-
deficient platelets in the absence of exogenous S1P, we did not
observe protection from thrombosis in mice with MK-selective Sphk
deficiency.6 Our current study shows no effect of S1pr1 deletion in
assays in which we observed clear effects of Sphk deficiency,6
arguing against an autocrine platelet signaling loop involving S1P1.
S1P1 modulation was shown to affect human platelet activation in
whole blood,7 and it is possible that another S1P receptor takes on
this function in mice, and that S1P1 plays a more important role in
humans. Yet as plasma S1P should already saturate S1P1,
54,55 it is
unclear how platelets would sense further elevation of S1P levels
after platelet activation by an S1P1-dependent mechanism.
Whereas the current dogma would predict substantial effect
of S1P1 modulation on platelet counts and thrombosis, our
observations argue that these effects are likely to be minimal. Even
if developmental deficiency of S1P1 in Mx1Cre-sensitive cells
resulted in a modest increase in platelet counts, this was not
observed with adult deletion, and neither chronic treatment with
oral fingolimod nor acute dosing with S1P1 modulators had a
measurable effect on platelet counts. In contrast, even partial
deficiency in Sphk2 reduced platelet counts by redistribution of
sphingosine to Sphk1, a kinase that is frequently upregulated in
cancer, inflammation, and other disease conditions. Increased Sphk1
activity in cells within the hematopoietic niche capable of S1P export
could thus be predicted to suppress platelet production. This could
be relevant to cancer, Gaucher disease, and other conditions in
which there is evidence of both S1P pathway deregulation and
thrombocytopenia.56
In conclusion, our observations argue that the S1P gradient and MK
S1P1 are both dispensable for platelet formation, and that S1P1 is
not critically involved in platelet activation or spreading in mice.
Although it remains possible that S1P1 is expressed and functional
on human MKs and platelets, the current model, which predicts that
S1P1 modulation could be associated with a risk of bleeding and
thrombosis, is based extensively on experiments performed in mice.
The model therefore warrants revision, especially in light of clinical
experience and with recent expansion of S1P1-directed therapies to
pathologies associated with considerable bleeding risk.
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